Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.
SHORT INTEREST
10M 07/31/19
P/E Current
-4.44
P/E Ratio (with extraordinary items)
-4.23
Average Recommendation: BUY
Average Target Price: 9.38
SHORT INTEREST
10M 07/31/19
P/E Current
-4.44
P/E Ratio (with extraordinary items)
-4.23
Average Recommendation: BUY
Average Target Price: 9.38
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media